Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Kooth PLC (KOO): The London-Listed Story That Could Surprise the Market Next

Kooth PLC (LSE: KOO), the AIM-quoted digital mental health provider, is shrinking at the top line while becoming markedly more profitable underneath. Its half-year trading update on 29 July 2026 guided to adjusted EBITDA of £5.0m to £5.4m for the six months to 30 …

Ankur Sharma | 03 September 2026

NIOX Group Plc (NIOX): Could This London Stock Be One of 2026's Most Overlooked Stories?

NIOX Group Plc (LSE: NIOX) came within a whisker of leaving the London market last year. Keensight Capital's indicative 81p-a-share approach in March 2025 won a "minded to recommend" from the board, only for the private equity firm to walk away in April citing …

Ankur Sharma | 03 September 2026

Solvonis Therapeutics Plc (SVNS): Could the Next Clinical or Commercial Catalyst Transform the Story?

The question is whether the pipeline can deliver a catalyst big enough to change the narrative before the next cheque is needed. Solvonis has a Phase 3 asset in severe alcohol use disorder, a US programme approaching an IND filing and a discovery compound …

Divya Sood | 03 September 2026

Oxford BioMedica plc (OXB): Could This London Stock Be One of 2026's Most Overlooked Stories?

Six months ago Oxford Biomedica plc (LSE: OXB) was the subject of a private-equity approach; today it is a FTSE 250 cell and gene therapy manufacturer digesting a guidance cut and preparing to publish half-year results on 22 September 2026. A walked-away bidder, a …

Ankur Sharma | 03 September 2026

Is Renalytix Plc (RENX) a Sleeper Stock Investors Should Be Watching in 2026?

Renalytix Plc (LSE:RENX) has spent two years shrinking, refinancing and rebuilding after its Nasdaq exit, largely out of the spotlight. On 1 September 2026 the AI-enabled kidney diagnostics group gave the market two reasons to look again: a multi-year collaboration with Quest Diagnostics, one …

Ankur Sharma | 03 September 2026

Futura Medical plc (FUM): Has the Market Given Up Too Soon on This Sexual Health Innovator?

Against that backdrop, Futura has won European clearance for a faster-acting version, Eroxon Intense, reported encouraging user data for its female sexual health gel WSD4000, and handed off US distribution to a new partner. With aMarket Valueof barely £2m, the pressing question is whether …

Divya Sood | 03 September 2026

Why Did Inspiration Healthcare Group Plc LSE:IHC Rise 2.05% Amid a firmer tone across London-listed medical technology shares?

Inspiration Healthcare Group Plc — LSE:IHC closed 2.05% higher on03 September 2026, with the shares at 19.39p after a gain of 0.39p on the day.

Ishan Mudgal | 03 September 2026

Why Did Ondine Biomedical Inc. LSE:OBI Close Unchanged Amid a steady tone across London-listed medical technology shares?

Ondine Biomedical Inc. — LSE:OBI closed unchanged on03 September 2026, with the shares at 11.50p and no net movement on the day.

Ishan Mudgal | 03 September 2026

Why Did TheraCryf Plc LSE:TCF Fall 5.05% Amid a softer tone across London-listed biotechnology shares?

TheraCryf Plc — LSE:TCF closed 5.05% lower on03 September 2026, with the shares at 0.1804p after a decline of 0.0096p on the day.

Ishan Mudgal | 03 September 2026

Why Did Fusion Antibodies Plc LSE:FAB Rise 1.66% Amid a firmer tone across London-listed biotechnology shares?

Fusion Antibodies Plc — LSE:FAB closed 1.66% higher on03 September 2026, with the shares at 12.20p after a gain of 0.20p on the day.

Ishan Mudgal | 03 September 2026
Support

Hi! How can we help you today?

Loading…